Perioperative atezolizumab + chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC

Patients with resectable signifier II–IIIB non-small compartment lung crab (NSCLC) treated with perioperative atezolizumab positive platinum-based chemotherapy experienced a median event-free endurance of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to last results from the Phase III IMpower030 trial.